Compare Deutsche Bank AG (DB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Smith & Nephew plc — how do they compare? Deutsche Bank AG trades at $38.26 (market cap $72.15B), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Deutsche Bank AG is far larger — about 5.8× Smith & Nephew plc's market cap, and Deutsche Bank AG pays the higher dividend (3.04%). Which is the better fit depends on your goals.
| DB | SNN | |
|---|---|---|
Market Cap | $72.15B | $12.50B |
Sector | Financials | Health |
52-Week High | $40.33 | $38.70 |
52-Week Low | $28.37 | $28.73 |
Dividend Yield | 3.04% | 2.64% |
Enterprise Value | — | $15.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $38.06, up 1.14% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with Q2 2026 revenue growth and a 10.02 P/E ratio trading below book value at 0.79. Recent developments include being named China's renminbi clearing bank and announcing a $500 million buyback. Net income margin improved to 22.04% in 2026, though Q2 earnings missed expectations.
DB presents a mixed investment case with attractive valuation metrics and strategic positioning in European banking, but faces execution risks from recent earnings miss and ongoing tax investigations. The stock trades at a discount to peers with moderate analyst support (21% buy rating) despite strong operational cash flow of $47.06 billion in 2025.
SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.
The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
